EUCTR2004-000759-40-IT进行中（未招募）不适用
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.
TEVA0 个研究点目标入组 25 人开始时间: 2005年2月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.EUCTR2004-000762-13-ITTEVA ITALIA srl7
进行中（未招募）
不适用
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).Relapsing-remitting multiple sclerosis (R-R MS)MedDRA version: 5.1Level: PTClassification code 10028245EUCTR2004-000463-94-HUTEVA Pharmaceutical Industries Ltd.25
进行中（未招募）
不适用
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).Subject with relapsing remitting multiple sclerosis. Subject must have at least one documented relapse within one year prior to screening visitMedDRA version: 6.1Level: PTClassification code 10028245EUCTR2004-000463-94-ITTEVA25
进行中（未招募）
不适用
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).Subjects with Relapsing-Remitting Multiple Sclerosis.Subjects must have had at least one documented relapse within one year prior to screening visitMedDRA version: 6.1Level: PTClassification code 10028245EUCTR2004-000462-13-ITTEVA
进行中（未招募）
不适用
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).Relapsing-remitting multiple sclerosis (R-R MS)MedDRA version: 5.1Level: PTClassification code 10028245EUCTR2004-000462-13-HUTEVA Pharmaceutical Industries Ltd.25